Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting
October 12, 2023 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and...
Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
October 03, 2023 08:30 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative...
Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023
September 11, 2023 16:06 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and...
Sight Sciences Appoints Matt Link as Chief Commercial Officer
September 11, 2023 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and...
Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference
August 30, 2023 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and...
Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
August 03, 2023 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing...
Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023
July 20, 2023 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology intended to...
Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye
July 20, 2023 08:30 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and...
Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)
June 21, 2023 08:30 ET
|
Sight Sciences, Inc.
Cigna has close to 15 million covered lives Cigna’s Coverage Policy includes procedures enabled with OMNI® Surgical System technology as medically necessary and covered MENLO PARK, Calif., June 21,...
Sight Sciences Announces Addition of New Director Catherine Mazzacco
June 09, 2023 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions...